Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD9833 (Camizestrant) in Japanese Women with Advanced Breast Cancer
NCT04541433Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2020
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of camizestrant in breast cancer, sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicity and Treatment-related adverse events up to 1 year. Started Sep 2020; status: completed.
02
Drugs
camizestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04541433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04541433.